BioCentury | Dec 5, 2018
Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
BioCentury | Jan 18, 2018
Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
BioCentury | Dec 8, 2017
Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
BioCentury | Dec 6, 2017
Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
Items per page:
1 - 4 of 4